Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients

Overview of attention for article published in New England Journal of Medicine, March 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

news: 33 news outlets
blogs: 2 blogs
twitter: 68 X users
facebook: 2 Facebook pages

video: 2 YouTube creators
guideline: 2 clinical guideline sources
bluesky: 1 Bluesky user
podcasts: 1 podcast

Readers on

mendeley: 108 Mendeley

So far, Altmetric has seen 75 X posts from 68 X users, with an upper bound of 2,597,360 followers.

NEJM：ONTRAC試験（2015年、386例）では、ニコチン酸アミドが免疫正常の高リスク者の新規非メラノーマ皮膚癌数を23％減少。ONTRANS試験（2023年、臓器移植患者158例）では207対210個で有意差なし。両試験とも500mgを1日2回、12か月投与した。 https://t.co/KUcaybBJHj https:…

RT @agingroy: Sources & Notes: The nicotinamide skin-cancer data: Chen AC et al., “A Phase 3 Randomized Trial of Nicotinamide for Skin-Ca…

Sources & Notes: The nicotinamide skin-cancer data: Chen AC et al., “A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention” (the ONTRAC trial). N Engl J Med 2015;373:1618-1626. https://t.co/W99cMeIXrZ 386 immunocompetent adults with…

Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients https://t.co/kemLxfg76f

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 71 additional X posts.